Recombinant Anti-FRAT1 antibody [EPR3900] (ab108405)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR3900] to FRAT1
- Suitable for: WB, ICC/IF
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-FRAT1 antibody [EPR3900]
See all FRAT1 primary antibodies -
Description
Rabbit monoclonal [EPR3900] to FRAT1 -
Host species
Rabbit -
Tested applications
Suitable for: WB, ICC/IFmore details
Unsuitable for: IHC-P -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: HeLa and MCF7 cell lysates ICC/IF: HeLa cells
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 50% Tissue culture supernatant -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR3900 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab108405 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/10000. Predicted molecular weight: 29 kDa.
|
|
ICC/IF |
1/250.
|
Notes |
---|
WB
1/1000 - 1/10000. Predicted molecular weight: 29 kDa. |
ICC/IF
1/250. |
Target
-
Relevance
The protein encoded by the FRAT1 gene belongs to the GSK-3-binding protein family. The protein inhibits GSK-3-mediated phosphorylation of beta-catenin and also positively regulates the Wnt signaling pathway. It may play a role in tumor progression and in lymphomagenesis. -
Cellular localization
Cytoplasmic -
Database links
- Entrez Gene: 10023 Human
- Entrez Gene: 14296 Mouse
- Omim: 602503 Human
- SwissProt: Q92837 Human
- SwissProt: P70339 Mouse
-
Alternative names
- FRAT 1 antibody
- frequently rearranged in advanced T cell lymphomas antibody
- Frequently rearranged in advanced T-cell lymphomas antibody
see all
Images
-
All lanes : Anti-FRAT1 antibody [EPR3900] (ab108405) at 1/1000 dilution
Lane 1 : HeLa cell lysate
Lane 2 : MCF7 cell lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 29 kDa -
Immunocytochemistry/ Immunofluorescence analysis of HeLa (human cervix adenocarcinoma epithelial cell) cells labeling FRAT1 with purified ab108405 at 1/250 dilution (10 µg/mL). Cells were fixed in 4% Paraformaldehyde and permeabilized with 0.1% tritonX-100. Cells were counterstained with ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) 1/200 (2.5 µg/mL). Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) was used as the secondary antibody at 1/1000 (2 µg/mL) dilution. DAPI (blue) was used as nuclear counterstain. ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) 1/200 (2.5 µg/mL) was used as the secondary antibody only control.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (8)
ab108405 has been referenced in 8 publications.
- Cai X et al. LncRNA CCAT1 promotes prostate cancer cells proliferation, migration, and invasion through regulation of miR-490-3p/FRAT1 axis. Aging (Albany NY) 13:18527-18544 (2021). PubMed: 34319909
- Guo G et al. STAT1 is a modulator of the expression of frequently rearranged in advanced T-cell lymphomas 1 expression in U251 cells. Oncol Lett 20:248-256 (2020). PubMed: 32565951
- Li B et al. Network-Wide Screen Identifies Variation of Novel Precise On-Module Targets Using Conformational Modudaoism. CPT Pharmacometrics Syst Pharmacol 7:16-25 (2018). IP . PubMed: 28925077
- Werner TV et al. MiR-34a-3p alters proliferation and apoptosis of meningioma cells in vitro and is directly targeting SMAD4, FRAT1 and BCL2. Aging (Albany NY) 9:932-954 (2017). WB . PubMed: 28340489
- Zhu K et al. FRAT1 expression regulates proliferation in colon cancer cells. Oncol Lett 12:4761-4766 (2016). PubMed: 28101222
- Zhang W et al. Frequently rearranged in advanced T-cell lymphomas-1 demonstrates oncogenic properties in prostate cancer. Mol Med Rep 14:3551-8 (2016). WB . PubMed: 27599661
- Yu Q et al. Silencing of FRAT1 by siRNA inhibits the proliferation of SGC7901 human gastric adenocarcinoma cells. Biomed Rep 4:223-226 (2016). PubMed: 26893843
- Jin R et al. The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear translocation of ß-catenin through mechanisms involving FRAT1 and PAK4. J Cell Sci 127:3116-30 (2014). Human . PubMed: 24829151